Cargando…
The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker”
BACKGROUND: Blood uric acid level indicates an emerging biomarker in Parkinson's disease (PD). This study aimed to evaluate longitudinal uric acid levels among different kinds of glucocerebrosidase (GBA) mutations and to compare it among sporadic PD, genetic cohort Parkinson's disease (GEN...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798165/ https://www.ncbi.nlm.nih.gov/pubmed/36590455 http://dx.doi.org/10.1016/j.prdoa.2022.100177 |
_version_ | 1784860848113582080 |
---|---|
author | Mozafar, Mehrdad Kazemian, Sina Hoseini, Elahe Mohammadi, Mohammad Alimoghadam, Rojina Shafie, Mahan Mayeli, Mahsa |
author_facet | Mozafar, Mehrdad Kazemian, Sina Hoseini, Elahe Mohammadi, Mohammad Alimoghadam, Rojina Shafie, Mahan Mayeli, Mahsa |
author_sort | Mozafar, Mehrdad |
collection | PubMed |
description | BACKGROUND: Blood uric acid level indicates an emerging biomarker in Parkinson's disease (PD). This study aimed to evaluate longitudinal uric acid levels among different kinds of glucocerebrosidase (GBA) mutations and to compare it among sporadic PD, genetic cohort Parkinson's disease (GENPD), genetic cohort unaffected (GENUN), and healthy control (HC) patients. METHODS: We conducted a study on 654 individuals from the Parkinson's progression markers initiative (PPMI) database. Baseline characteristics, uric acid levels, movement disorder society unified Parkinson's disease rating scale III (MDS-UPDRS III), Hoehn and Yahr Parkinson stage (H&Y stage), and DaT scan specific binding ratio (SBR) data were obtained. Different GBA mutations were collected and categorized into three groups. Longitudinal measurements of uric acid and MDS-UPDRS III score were evaluated during 3-years of follow-up. RESULT: GENPD cohort exhibited a greater MDS-UPDRS III score, H&Y stage, and lower SBR in the right caudate, left caudate, and right putamen compared to sporadic PD. Baseline uric acid level was similar among all groups and different GBA variants. After adjustment for age, sex, and body mass index, the uric acid level was significantly lower in the GENPD group than in HC during year 2 (P-value: 0.009). No significant longitudinal differences were detected for the MDS-UPDRS III score and three groups of GBA mutations. CONCLUSION: This is the first study to assess uric acid levels and MDS-UPDRS III scores among different GBA mutation variants within 3 years of follow-up. We found similar clinical characteristics among different subtypes of GBA mutations. |
format | Online Article Text |
id | pubmed-9798165 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-97981652022-12-30 The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker” Mozafar, Mehrdad Kazemian, Sina Hoseini, Elahe Mohammadi, Mohammad Alimoghadam, Rojina Shafie, Mahan Mayeli, Mahsa Clin Park Relat Disord Original Article BACKGROUND: Blood uric acid level indicates an emerging biomarker in Parkinson's disease (PD). This study aimed to evaluate longitudinal uric acid levels among different kinds of glucocerebrosidase (GBA) mutations and to compare it among sporadic PD, genetic cohort Parkinson's disease (GENPD), genetic cohort unaffected (GENUN), and healthy control (HC) patients. METHODS: We conducted a study on 654 individuals from the Parkinson's progression markers initiative (PPMI) database. Baseline characteristics, uric acid levels, movement disorder society unified Parkinson's disease rating scale III (MDS-UPDRS III), Hoehn and Yahr Parkinson stage (H&Y stage), and DaT scan specific binding ratio (SBR) data were obtained. Different GBA mutations were collected and categorized into three groups. Longitudinal measurements of uric acid and MDS-UPDRS III score were evaluated during 3-years of follow-up. RESULT: GENPD cohort exhibited a greater MDS-UPDRS III score, H&Y stage, and lower SBR in the right caudate, left caudate, and right putamen compared to sporadic PD. Baseline uric acid level was similar among all groups and different GBA variants. After adjustment for age, sex, and body mass index, the uric acid level was significantly lower in the GENPD group than in HC during year 2 (P-value: 0.009). No significant longitudinal differences were detected for the MDS-UPDRS III score and three groups of GBA mutations. CONCLUSION: This is the first study to assess uric acid levels and MDS-UPDRS III scores among different GBA mutation variants within 3 years of follow-up. We found similar clinical characteristics among different subtypes of GBA mutations. Elsevier 2022-12-17 /pmc/articles/PMC9798165/ /pubmed/36590455 http://dx.doi.org/10.1016/j.prdoa.2022.100177 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Original Article Mozafar, Mehrdad Kazemian, Sina Hoseini, Elahe Mohammadi, Mohammad Alimoghadam, Rojina Shafie, Mahan Mayeli, Mahsa The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker” |
title | The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker” |
title_full | The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker” |
title_fullStr | The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker” |
title_full_unstemmed | The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker” |
title_short | The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker” |
title_sort | glucocerebrosidase mutations and uric acid levels in parkinson’s disease: a 3-years investigation of a potential biomarker” |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798165/ https://www.ncbi.nlm.nih.gov/pubmed/36590455 http://dx.doi.org/10.1016/j.prdoa.2022.100177 |
work_keys_str_mv | AT mozafarmehrdad theglucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT kazemiansina theglucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT hoseinielahe theglucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT mohammadimohammad theglucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT alimoghadamrojina theglucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT shafiemahan theglucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT mayelimahsa theglucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT theglucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT mozafarmehrdad glucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT kazemiansina glucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT hoseinielahe glucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT mohammadimohammad glucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT alimoghadamrojina glucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT shafiemahan glucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT mayelimahsa glucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT glucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker |